by Halia Therapeutics | Sep 3, 2024 | Press Releases
LEHI, Utah , Sept. 3, 2024 /PRNewswire/ — Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for inflammatory and neurodegenerative diseases, today announced a pivotal... by James Dye | Aug 6, 2024 | Press Releases
Lehi, UT, August 6th, 2024/PRNewswire/ – Halia Therapeutics, a clinical-stage biopharmaceutical company, today announced that Dr. David J. Bearss, President and CEO, and a renowned drug developer, will be giving an oral presentation highlighting the company’s latest... by James Dye | Jul 31, 2024 | Press Releases
LEHI, Utah, July 31, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, and Biolexis Therapeutics, a biotechnology company... by James Dye | Jul 23, 2024 | Press Releases
David J. Bearss, PhD channels years of expertise to his work with Halia and Biolexis Therapeutics ALPINE, UT, July 19, 2024 /24-7PressRelease/ — David J. Bearss, PhD has been included in Marquis Who’s Who. As in all Marquis Who’s Who biographical... by James Dye | Jun 13, 2024 | Press Releases
NEWS PROVIDED BY Venture Capital PodcastJun 13, 2024, 00:35 ET The 2024 list celebrates the Founder 100 driving innovation and growth in the Utah community LEHI, Utah, June 13, 2024 /PRNewswire/ — Today, the Venture Capital Podcast unveiled its Founder... 
by James Dye | May 29, 2024 | Press Releases
Preliminary safety, efficacy, and biomarker data from the ongoing Phase II trial evaluating HT-6184 inMDS patients will be presented at the EHA 2024 Hybrid Congress. LEHI, Utah, May 29, 2024 /PRNewswire/... by James Dye | May 14, 2024 | Press Releases
CEO Dave Bearss, Ph.D., will be participating in a panel discussing the “Landscape of Drug Discovery and Impact of AI Discussion” on Wednesday, May 22, from 1:50 to 2:30 p.m. CEST Company presentation to unveil new data from HT-4253 in its new clinical... 
by James Dye | Apr 17, 2024 | Press Releases
*Presentation to be held on Wednesday, April 24, from 2:00 – 2:15 p.m. SGT LEHI, Utah, April 17, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat... by James Dye | Mar 12, 2024 | Press Releases
Presentation to be held on Tuesday, March 19, from 11:30 a.m. – 11:45 a.m. CET LEHI, Utah, March 12, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule... by James Dye | Feb 21, 2024 | Press Releases
LEHI, Utah, Feb. 21, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that David J. Bearss, Ph.D., President and CEO of... by James Dye | Feb 15, 2024 | Press Releases
The first patient undergoing wisdom tooth extraction has been dosed with HT-6184 to evaluate its effect on post-procedure diagnostic biomarkers of inflammation and pain, as well as to evaluate its safety and tolerability. LEHI, Utah, Feb. 15,... 
by Halia Therapeutics | Feb 6, 2024 | Press Releases
This technology will support the development of Halia’s new Alzheimer’s disease drug, HT-4253, targeting a mediator of neuroinflammation called Leucine-rich repeat kinase 2 (LRRK2) LEHI,... 
by Halia Therapeutics | Jan 31, 2024 | Press Releases
Series C Financing will support the advancement of lead programs in Phase II clinical trials, evaluating HT-6184, Halia’s first-in-class NLRP3/NEK7 inflammasome inhibitor, and advancing additional programs into the clinic. LEHI, Utah, January 31,... by Halia Therapeutics | Jan 4, 2024 | Press Releases
LEHI, Utah, Jan. 4, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company, is pioneering a novel class of small molecule medications designed to combat inflammation. Today, the company announced that its leadership team will attend... by Halia Therapeutics | Dec 15, 2023 | Press Releases
LEHI, Utah, Dec. 15, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that the company will present at the 13th... 
by Halia Therapeutics | Dec 13, 2023 | Press Releases
LEHI, Utah, Dec. 13, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the dosing of the first patient in Phase 2a clinical... 
by Halia Therapeutics | Dec 8, 2023 | Press Releases, News & Media
The Phase II trial of HT-6184 will enroll around 50 patients with MDS who are or are on the borderline of being transfusion-dependent. Halia Therapeutics is looking to start a Phase II trial of its pipeline candidate HT-6184 in myelodysplastic syndrome (MDS) early... 
by Halia Therapeutics | Nov 29, 2023 | News & Media, Press Releases
LEHI, Utah, Nov. 29, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced positive results following the... by Halia Therapeutics | Nov 27, 2023 | Press Releases
Halia will present 3 posters with new positive data and a company showcase providing an overview of its clinical programs targeting the inflammasome LEHI, Utah, Nov. 27, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company... 
by Halia Therapeutics | Nov 20, 2023 | Press Releases
LEHI, Utah, Nov. 20, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced...